Butanedioic acid;propane-1,2,3-triol | 69552-98-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Butanedioic acid;propane-1,2,3-triol
• CAS: 69552-98-3
• 化学式: C7H14O7
• 分子量: 210.18
• InChiKey: WKZFQFQFYZJKPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.73
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  135
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Polycarboxylic acid compounds for the treatment of fibrious amino acid based substrates, especially hair
  申请人：Momentive Performance Materials, Inc.

  公开号：US10617617B1

  公开（公告）日：2020-04-14

  This invention relates to the use of polycarboxylic acid compounds, aqueous compositions comprising the same, cosmetic compositions comprising the same, in particular, hair care compositions, and their use for the treatment of hair, and a process for the treatment of hair comprising the use of said cosmetic compositions.

  本发明涉及使用多羧酸化合物，包含它们的水性组合物，包含它们的化妆品组合物，特别是头发护理组合物，以及它们用于头发治疗的用途，以及包含使用该化妆品组合物的头发处理过程。
• Fatty acid esters composition of a polyglycerine, a process for the preparation thereof, a process for the preparation of a highly-purified fatty acid esters composition of a polyglycerine, a highly-purified fatty acid esters composition of a polyglycerine, an additive for food-stuffs, a resin composition, and a composition for cosmetic or detergents
  申请人：——

  公开号：US20040197460A1

  公开（公告）日：2004-10-07

  Disclosed are a fatty acid esters composition of a polyglycerine containing more than 70% of a fatty acid monoester which is defined by a specified analysis method, a process for the preparation thereof, a process for the preparation of a highly-purified fatty acid esters composition of a polyglycerine, and a highly-purified fatty acid esters composition of a polyglycerine having an oxirane oxygen concentration of below 100 ppm which is defined by a specified analysis method. The fatty acid esters compositions of a polyglycerine are useful as additives for a variety of food-stuffs, additives for a variety of thermoplastic resins, and as additives for a variety of cosmetics or detergents.

  本发明涉及一种脂肪酸酯组合物，其中包含超过70％的脂肪酸单酯，该脂肪酸单酯由指定的分析方法定义，以及其制备方法，制备高度纯化的聚甘油脂肪酸酯组合物的方法，以及具有低于100 ppm的环氧氧含量的聚甘油脂肪酸酯组合物，该组合物由指定的分析方法定义。聚甘油脂肪酸酯组合物可用作各种食品添加剂、各种热塑性树脂的添加剂，以及各种化妆品或清洁剂的添加剂。
• Sustained release pharmaceutical formulation for inhalation
  申请人：——

  公开号：US20040105821A1

  公开（公告）日：2004-06-03

  Pharmaceutical formulations and methods are provided for the sustained delivery of a pharmaceutical agent to the lungs of a patient by inhalation. The formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein upon inhalation of the formulation a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles in the lungs for at least 2 hours. Preferably, a majority of the pharmaceutical agent is released from the microparticles by 24 hours following inhalation, for example where a majority of the pharmaceutical agent is released no earlier than about 2 hours and no later than about 24 hours following inhalation. Methods for delivering a pharmaceutical agent, such as a corticosteroid, to the lungs of a patient are also provided. For example, the method includes having the patient inhale a dry powder blend comprising the present microparticles and a pharmaceutically acceptable bulking agent.

  提供了一种药物制剂和方法，通过吸入将药物剂量持续释放到患者的肺部。该制剂包括多孔微粒，其中包括药物剂量和基质材料，吸入该制剂后，肺部至少释放出治疗或预防有效剂量的药物剂量，持续时间至少为2小时。最好，药物剂量的大部分在吸入后的24小时内从微粒中释放出来，例如，药物剂量的大部分在吸入后不早于约2小时，不晚于约24小时内释放。还提供了将药物剂量（例如皮质类固醇）传递到患者肺部的方法。例如，该方法包括让患者吸入包括当前微粒和药用可接受的增容剂的干粉混合物。
• Fatty acid esters composition of a polyglycerine, a process for the preparation thereof, a process for the preparation of a highly-purified fatty acid esters composition of a polyglycerine, a highly-purified fatty acid esters composition of a polyglycerine, an additive for food-stuffs, a resin composition, and a composition for cosmetics or detergents
  申请人：——

  公开号：US20040024233A1

  公开（公告）日：2004-02-05

  Disclosed are a fatty acid esters composition of a polyglycerine containing more than 70% of a fatty acid monoester which is defined by a specified analysis method, a process for the preparation thereof, a process for the preparation of a highly purified fatty esters composition of a polyglycerine, and a highly-purified fatty acid esters composition of a polyglycerine having an oxirane oxygen concentration of below 100 ppm which is defined by a specified analysis method. The fatty acid esters compositions of a polyglycerine are useful as additives for a variety of food-stuffs, additives for a variety of thermoplastic resins, and as additives for a variety of cosmetics or detergents.

  本发明涉及一种脂肪酸酯组合物，其包含70％以上的脂肪酸单酯，该单酯由指定的分析方法定义，以及其制备方法，高度纯化的聚甘油脂肪酸酯组合物的制备方法和具有氧环氧氧浓度低于100 ppm的高度纯化的聚甘油脂肪酸酯组合物，该组合物由指定的分析方法定义。聚甘油脂肪酸酯组合物可用作各种食品添加剂、各种热塑性树脂的添加剂以及各种化妆品或洗涤剂的添加剂。
• Injectable, oral, or topical sustained release pharmaceutical formulations
  申请人：Bernstein Howard

  公开号：US20050069591A1

  公开（公告）日：2005-03-31

  Pharmaceutical formulations and methods are provided for the sustained delivery of a pharmaceutical agent to a patient by injection, by oral administration or by topical administration. The injectable formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein upon injection of the formulation a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles for at least 24 hours. The oral formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles for at least 2 hours following oral administration. The topical formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein a therapeutically or prophylactically effective amount of the pharmaceutical agent is released from the microparticles for at least 2 hours following topical administration.

  提供了药物制剂和方法，通过注射、口服或局部给药使药物代理持续释放给患者。可注射的制剂包括多孔微粒，其包括药物代理和基质材料，在注射制剂后，药物代理的治疗或预防有效量将从微粒中释放至少24小时。口服制剂包括多孔微粒，其包括药物代理和基质材料，在口服后，药物代理的治疗或预防有效量将从微粒中释放至少2小时。局部制剂包括多孔微粒，其包括药物代理和基质材料，在局部给药后，药物代理的治疗或预防有效量将从微粒中释放至少2小时。